

# Agenda



## Vaccine Virtual Days

Vaccination during COVID-19:  
Extraordinary challenges call for  
extraordinary connections

Save the date:  
29-30 June,  
2020



# Agenda

Day 1

29<sup>th</sup> June

13:00-21:00 (GMT+1 Belgium)

# Agenda

Day 1 – 29 <sup>th</sup> June		13:00-16:35 (GMT+1 Belgium)	
<b>Session: Life course immunization</b>			
Session: 215 min			
13:00-13:15	Opening by Scientific Committee member 15'		(Scientific Committee - TBC)
Life course immunization: sub-session 1			
	<b>Topic</b>	<b>Format</b>	<b>Moderators – Markus Knuf and Paolo Bonanni</b>
13:15-13:25	Life course immunization	Introduction 10'	Paolo Bonanni and Markus Knuf
13:25-13:50	Innovative methods for vaccinations delivery	Best practice sharing: Mobile unit for pediatric vaccination 5' Drive-through clinics 5' Communication campaign around vaccination during pandemic 5' Discussion + Q&A 10'	<b>Chair Markus</b> Speakers: Mona Doss (USA) Rodney Pearce (Australia) Dr Hien Minh Nguyen (Vietnam)
13:50-13:55	Topic Break 5'		
13:55-14:25	Rationale for NITAG recommendations, ways of working	Round table discussion 30' Decision making process of recommendation bodies: Different countries – different decisions	<b>Chair: Paolo Bonanni</b> Speakers: Paolo Bonanni (Italy) Thomas Weinke (Germany) (TBC) Shamez Ladhani (UK)
14:25-14:40	Sub-session Break 15'		
Life course immunization: sub-session 2			
	<b>Topic</b>	<b>Format</b>	<b>Moderators – Markus Knuf and Paolo Bonanni</b>
14:40-15:10	Maternal immunization	Round table discussion Current concepts and future directions 20' Discussion + Q&A 10'	<b>Chair: Paolo Bonanni and Markus Knuf</b> Speakers: Flor Munoz (USA) Elke Leuridan (Belgium)
15:10-15:15	Topic Break 5'		
15:15-15:45	Vaccination of older adults	Benefit of vaccination for older adults 15' (Examples: Tdap, Flu, shingles) Older adults, how to reach? 10' Discussion + Q&A 5'	<b>Chair: Paolo Bonanni</b> Speakers: Jean-Pierre Michel (Switzerland) Stefania Maggi (Italy)
15:45-15:50	Topic Break 5'		
15:50-16:20	Vaccination of special groups	Vaccination of preterm 10' Vaccination of special groups 10' Discussion + Q&A 10'	<b>Chair: Paolo Bonanni</b> Speakers: Markus Knuf (Germany) Susanna Esposito (Italy)
16:20-16:35	Session Break 15'		

# Agenda

Day 1 – 29 <sup>th</sup> June		16:35-18:30 (GMT+1 Belgium)	
Session: Nonspecific vaccine effects			
Session: 100 min			
	Topic	Format	Moderator – Marco Safadi
16:35-16:45	Nonspecific effects of vaccines	Introduction <b>10'</b>	Marco Safadi (Brazil)
16:45-17:00	Trained immunity: a memory for innate host defense	Talk <b>15'</b>	Speakers: Mihai Netea (The Netherlands)
17:00-17:15	BCG From ecological studies to evidence from clinical trials or is there reliable data showing any impact of BCG on COVID-19 risk?	Talk <b>15'</b>	Speakers: Nigel Curtis (Australia) (TBC)
17:15-17:30	Impact of early measles vaccination on mortality and the role of memory B cells	Talk <b>15'</b>	Speakers: Federico Martinón Torres (Spain)
17:30-17:45	Impact of influenzae vaccines in respiratory infections	Talk <b>15'</b>	Speaker: Albert Osterhaus (Germany)
17:45-18:15	Discussion	Q&A <b>30'</b>	Moderator: Marco Safadi Speakers: All
18:15-18:30	Session Break <b>15'</b>		

# Agenda

Day 1 – 29 <sup>th</sup> June		18:30-21:00 (GMT+1 Belgium)	
<b>Session: Assessing Vaccine Safety and Confidence in the Covid-19 era. What needs to be done?</b>			
Session: 150 min			
	Topic	Format	Moderator – Steve Black
18:30-18:35	Vaccine Safety and Confidence	Introduction 5'	Steve Black (USA)
<b>Vaccine Safety and Confidence: Sub-session 1</b>			
18:35-18:50	Vaccine confidence in the age of coronavirus including impact of covid19 on vaccination programs	Talk 15'	Speakers: Heidi Larson (UK)
18:50-19:05	HPV vaccine and vaccine confidence; what did go wrong? How can this approach inform covid19 vaccine?	Talk 15'	Speakers: Margaret Stanley (UK)
19:05-19:15	Discussion	Q&A 10'	Moderator: Steve Black Speakers: Heidi Larson (UK) Margaret Stanley (UK)
19:15-19:20	<b>Topic Break 5'</b>		
19:20-19:35	Will America accept a COVID19 vaccine?	Talk 15'	Speakers: Peter Hotez (USA)
19:35-19:50	Enhanced disease. How to assess it and how to minimize risk? Considerations for covid19 vaccines development?	Talk 15'	Speakers: Paul-Henri Lambert (Switzerland)
19:50-20:05	Vaccine assessment after vaccine introduction. How to keep the public informed?	Talk 15'	Speakers: Miriam Sturkenboom (The Netherlands)
20:05-20:15	Discussion	Q&A 10'	Moderator: Steve Black Speakers: Peter Hotez (USA) Paul-Henri Lambert (Switzerland) Miriam Sturkenboom (The Netherlands)
20:15-20:30	<b>Sub-session Break 15'</b>		
<b>Vaccine Safety and Confidence: Sub-session 2</b>			
20:30-21:00	Participants from vx developers (both presenters and new), regulators  Challenges associated with covid vx development and implementation: safety, enhanced disease, upscale/production/distribution, effectiveness in the long term (boosters required?), how can we maximize vaccines confidence?	Round Table 30'	Moderator: Steve Black Speakers: David Salisbury (UK) Heidi Larson (UK) (TBC) Hanneke Schuitemaker (The Netherlands) (TBC) Thomas Breuer (GSK)

# Agenda

Day 2  
30<sup>th</sup> June

14:00-21:45 (GMT+1 Belgium)

# Agenda

Day 2 – 30 <sup>th</sup> June		14:00-16:30 (GMT+1 Belgium)	
Session: Respiratory pathogens: focus on SARS-CoV-2/COVID19			
Session: 150 min			
	Topic	Format	Moderator – Dr. Philippe Buchy
14:00-14:15	<b>Opening by Scientific Committee member 15'</b>		(Scientific Committee - TBC)
14:15-14:30	<b>Immune response to SARS-CoV-2 infection: how does it compare to other respiratory pathogens?</b> Humoral and cellular responses to SARS-CoV-2: what we do know, what we don't know, what are the learnings from SARS-CoV and MERS-CoV studies that could be potentially be extrapolated to SARS-CoV-2?	Talk 15'	Prof Malik Peiris (Hong-Kong)
14:30-14:35	Discussion	Q&A 5'	Moderator: Dr. Philippe Buchy Speaker: Prof Malik Peiris (Hong-Kong)
14:35-14:50	<b>Pathogenesis of COVID19: is it something unique?</b> Immunopathogenesis of severe COVID19 cases: role of the virus, the receptor expression and the host immune response. How it impacts the way we may have to design vaccine development strategies?	Talk 15'	Speakers: Prof Malik Peiris (Hong-Kong)
14:50-14:55	Discussion	Q&A 5'	Moderator: Dr. Philippe Buchy Speakers: Prof Malik Peiris (Hong-Kong)
14:55-15:00	<b>Topic Break 5'</b>		
15:00-15:15	<b>Clinical features of COVID19: from asymptomatic infection to deadly disease</b> Spectrum of disease with focus on severe cases Clinical features more specifically/frequently observed with COVID19 compared to SARS, MERS, other severe respiratory diseases (e.g., anosmia/dysgeusia, digestive symptoms, etc.); Kawasaki-like disease in children?	Talk 15'	Speakers: Prof David Hui (Hong-Kong)
15:15-15:20	Discussion	Q&A 5'	Moderator: Dr. Philippe Buchy Speakers: Prof David Hui (Hong-Kong)
15:20-15:35	<b>New therapeutic strategies for COVID19: what are the challenges?</b> Antivirals, immunomodulators, plasmatherapy, etc.: the proven and the unproven	Talk 15'	Speakers: Prof David Hui (Hong-Kong)
15:35-15:40	Discussion	Q&A 5'	Moderator: Dr. Philippe Buchy Speakers: Prof David Hui (Hong-Kong)
15:40-15:45	<b>Topic Break</b>		
15:45-16:15	<b>The known unknown and the unknown known</b>	Round table discussion 30' Q&A	Moderator: Dr. Philippe Buchy Speakers: Prof Malik Peiris (Hong-Kong) Prof David Hui (Hong-Kong)
16:15-16:30	<b>Session Break 15'</b>		

# Agenda

Day 2 – 30 <sup>th</sup> June		16:30-19:25 (GMT+1 Belgium)	
Session: Vaccine Development			
Session: 175 min			
	Topic	Format	Moderators – Stanley Plotkin & Albert Osterhaus
16:30-16:35	Vaccine development	Introduction 5'	Stanley Plotkin or Albert Osterhaus
Vaccine Development: Sub-session 1			
16:35-16:55	<b>Overview general vaccine development:</b> Preclinical/clinical/PM Regulatory considerations in evaluating vaccine safety and efficacy	General vaccine development (1) 10' General vaccine development (2) 10'	Speakers: Bart Haagmans (The Netherlands) Philip Krause (USA)
16:55-17:05	Discussion	Q&A 10'	Moderator: Stanley Plotkin Speakers: Speakers: Bart Haagmans (The Netherlands) Philip Krause (USA)
17:05-17:35	<b>Traditional technology platforms:</b> Live attenuated, inactivated Polysaccharide conjugate Subunits - recombinant proteins and VLPs	Traditional technology platforms (1) 10' Traditional technology platforms (2) 10' Traditional technology platforms (3) 10'	Speakers: Stanley Plotkin (USA) George Siber (USA) Berend-Jan Bosch (The Netherlands)
17:35-17:45	Discussion	Q&A 10'	Moderator: Albert Osterhaus Speakers: George Siber (USA) Berend-Jan Bosch (The Netherlands)
17:45-18:00	Sub-session Break 15'		
Vaccine Development: Sub-session 2			
18:00-18:20	<b>Newer technology platforms:</b> Reverse vaccinology/structural vaccinology Adjuvants	Newer technology (1) 10' Newer technology (2) 10'	Speakers: Rino Rappuoli (GSK) Thomas Breuer (GSK)
18:20-18:30	Discussion	Q&A 10'	Moderator: Albert Osterhaus Speakers: Rino Rappuoli (GSK) Thomas Breuer (GSK)
18:30-19:00	<b>Emerging technology platforms</b> Nucleic acid – DNA Nucleic acid – RNA Vectors	Emerging platforms (1) 10' Emerging platforms (2) 10' Emerging platforms (3) 10'	Speakers: David Weiner (USA) Drew Weisman (USA) Hanneke Schuitemaker (USA)
19:00-19:10	Discussion	Q&A 10'	Moderator: Stanley Plotkin Speakers: David Weiner (USA) Drew Weisman (USA) Hanneke Schuitemaker (USA)
19:10-19:25	Session Break 15'		



# Agenda

Day 2 – 30 <sup>th</sup> June			19:25-21:45 (GMT+1 Belgium)
Session: Antimicrobial Resistance			
Session: 150 min			
	Topic	Format	Moderator – Ian Feavers
19:25-19:30	Antimicrobial Resistance	Introduction 5'	Ian Feavers
Antimicrobial Resistance: Sub-session 1			
19:30-19:45	Outline of the AMR problem	Talk 10' + Q&A 5'	Speaker: Jim O'Neill (UK)
19:45-20:00	Antibiotics and evolution	Talk 10' + Q&A 5'	Speakers: Gordon Dougan (UK)
20:00-20:15	The role and advantages of vaccines in reducing AMR	Talk 10' + Q&A 5'	Speaker: Rino Rappuoli (GSK)
20:15-20:30	Role of biological standards in reducing AMR	Talk 10' + Q&A 5'	Speakers: Ian Feavers (TBC)
20:30-20:45	Sub-session Break 15'		
Antimicrobial Resistance: Sub-session 2			
20:45-21:45	<b>Vaccine pipelines</b>		Speakers:
	Enterics (Shigella, <i>E.coli</i> , NT-Salmonella)	Talk 10' + Q&A 5'	Calman MacLennan (UK)
	Progresses on Gonococcal vaccines	Talk 10' + Q&A 5'	Kate Seib (Australia)
	Progresses on TB vaccines	Talk 10' + Q&A 5'	Ann Ginsberg (USA)
	Progresses on Malaria vaccines	Talk 10' + Q&A 5'	Dr. Ashly Birkett (USA)